QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NYSE:OGN

Organon & Co. (OGN) Stock Price, News & Analysis

$17.79
+0.08 (+0.45%)
(As of 04:10 PM ET)
Today's Range
$17.38
$17.92
50-Day Range
$16.13
$18.80
52-Week Range
$10.84
$24.79
Volume
2.50 million shs
Average Volume
2.77 million shs
Market Capitalization
$4.55 billion
P/E Ratio
4.45
Dividend Yield
6.30%
Price Target
$21.80

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
22.9% Upside
$21.80 Price Target
Short Interest
Bearish
4.28% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.37
Upright™ Environmental Score
News Sentiment
1.11mentions of Organon & Co. in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$49,939 Bought Last Quarter
Proj. Earnings Growth
2.94%
From $4.08 to $4.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.76 out of 5 stars

Medical Sector

43rd out of 930 stocks

Pharmaceutical Preparations Industry

16th out of 428 stocks

OGN stock logo

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

OGN Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
OGN Quantitative Stock Analysis
Organon & Co (OGN)
Organon's Valuation Is Not Expensive
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Organon Stock Is Still Worth A Look
Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript
Organon Stock (NYSE:OGN), Guidance and Forecast
Looking Into Organon's Recent Short Interest
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Ex-Dividend for 3/14 Dividend
2/23/2024
Dividend Payable
3/14/2024
Today
4/16/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
10,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.80
High Stock Price Target
$28.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+22.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
10.75%

Debt

Sales & Book Value

Annual Sales
$6.26 billion
Cash Flow
$5.13 per share
Book Value
($0.27) per share

Miscellaneous

Free Float
252,647,000
Market Cap
$4.55 billion
Optionable
Not Optionable
Beta
0.82
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Kevin Ali (Age 64)
    CEO & Director
    Comp: $3.96M
  • Mr. Matthew M. Walsh (Age 57)
    Executive VP & CFO
    Comp: $1.84M
  • Ms. Susanne Gabriele Fiedler (Age 55)
    Executive VP & Chief Commercial Officer
    Comp: $1.44M
  • Mr. Joseph T. Morrissey Jr. (Age 58)
    Executive VP and Head of Manufacturing & Supply
    Comp: $1.54M
  • Ms. Rachel A. Stahler (Age 48)
    Executive VP & Chief Information Officer
  • Ms. Jennifer Halchak
    Head of Investor Relations
  • Mr. Kirke Weaver (Age 50)
    Executive VP, General Counsel & Corporate Secretary
  • Ms. Susan O'Neal
    Chief Ethics & Compliance Officer
  • Ms. Rebecca Lowell Edwards
    Chief Communications Officer
  • Mr. Daniel Karp (Age 46)
    Chief Business Development Officer

OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price target for 2024?

4 brokers have issued 1-year price objectives for Organon & Co.'s shares. Their OGN share price targets range from $18.00 to $28.00. On average, they predict the company's stock price to reach $21.80 in the next year. This suggests a possible upside of 22.9% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2024?

Organon & Co.'s stock was trading at $14.42 on January 1st, 2024. Since then, OGN stock has increased by 23.0% and is now trading at $17.74.
View the best growth stocks for 2024 here
.

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OGN earnings forecast
.

How can I listen to Organon & Co.'s earnings call?

Organon & Co. will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) released its quarterly earnings results on Thursday, February, 15th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.14. The company earned $1.60 billion during the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative trailing twelve-month return on equity of 212.00%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Thursday, February 15th. Shareholders of record on Monday, February 26th will be given a dividend of $0.28 per share on Thursday, March 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.31%. The ex-dividend date is Friday, February 23rd.
Read our dividend analysis for OGN
.

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.42%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 28.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.67% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.4 billion.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a number of institutional and retail investors. Top institutional investors include Gilman Hill Asset Management LLC (0.26%), Sound Income Strategies LLC (0.21%), Douglas Lane & Associates LLC (0.19%), Los Angeles Capital Management LLC (0.07%), Alaska Permanent Fund Corp (0.06%) and Register Financial Advisors LLC (0.02%). Insiders that own company stock include Kirke Weaver and Ma Fatima Francisco.
View institutional ownership trends
.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners